Veru Reports Fiscal 2024 First Quarter Financial Highlights
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone—
Related news for (VERU)
- Veru to Participate in the Virtual BTIG Obesity Health Forum
- Biotech Today: From Sustainable Biomaterials to First-in-Class Therapies
- Today’s Top Performers: MoBot’s Market Review 05/28/25 07:00 AM
- Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
- Today’s Top Performers: MoBot’s Market Review 05/28/25 06:00 AM